Cell therapy CDMO BioCentriq has signed a long-term lease agreement for a cell therapy manufacturing facility in Princeton, New Jersey, which will serve as the company's new headquarters.
According to BioCentriq, the CDMO will make an immediate $12 million capital investment in facility upgrades, equipment, and business system enhancements.
Spanning approximately 60,000 sq. ft., the site features six independent ISO 7 cleanrooms, equipped with cutting-edge manufacturing technologies, including advanced bioreactors, automated cell processing systems, and scalable production platforms. With a proven track record in cell therapy manufacturing, the site operates under current GMP regulatory standards and industry guidelines and offers 30,000 sq. ft. of expansion space to accommodate additional clinical and commercial-scale production capacity.
This expansion builds on BioCentriq's established presence in New Jersey. The CDMO has a process development pilot plant in South Brunswick and a GMP, ISO-7 certified clinical manufacturing facility on the campus of NJIT in Newark. The Newark facility, featuring two independent ISO 7 cleanrooms, an integrated quality control lab, and extensive support infrastructure, serves as a clinical GMP production center and the company's hub for specialized training and workforce development.
The investment in the Princeton facility is expected to be completed and the facility fully operational by Q2 2025, with manufacturing services available immediately thereafter. Process and analytical development services are expected to be available in Q1 2025.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!